The World Health Organization (WHO) Clean Care is Safer Care global programme is based around a change model. It fosters partnerships and coordinates activities as set out in its programme plan. By May 2016, more than 140 of the 194 United Nations' member states had pledged their support to implement actions to reduce healthcare-associated infections, corresponding to 95% coverage of the world population.
Background: Zika virus (ZIKV), a recently emerged flaviviral pathogen, has been linked to microcephaly in neonates. Yet, it is not understood why some fetuses develop severe microcephaly due to maternal ZIKV infection while others do not. The risk for ZIKV-induced microcephaly is greatest during the first trimester of pregnancy in humans, yet this alone cannot account for the varied presentation of microcephaly observed. Given the antigenic similarity between ZIKV and closely related dengue virus (DENV), combined with the substantial immunity to DENV in ZIKV target populations in recent outbreaks, we hypothesized that maternal antibodies against DENV were a risk factor for ZIKV-induced microcephaly.
Methods & Materials: Using immune-competent mice, we developed a mouse model of maternal to fetal transmission of ZIKV infection. Mother mice were infected on embryonic day 7 (E7), an equivalent fetal developmental stage to the first trimester of human pregnancy. Microcephaly was assessed in the fetuses by measuring head circumference and cortical thickness on E18, near full-term. ZIKV replication was measured in the mothers and fetuses by real-time quantitative PCR, negative-strand PCR, and immunohistochemistry for multiple ZIKV proteins. To test the influence of DENV immunity on fetal infection, mothers that were DENV immune or that were given the flavivirus cross-reactive monoclonal antibody 4G2 were infected with ZIKV and their fetuses were examined. Mice deficient in the neonatal Fc receptor (FcRN), which is known to carry maternal antibodies into the fetus, were used to determine its role in vertical transmission of ZIKV infection.
Results: We observed disproportionate microcephaly and reduced cortical thickness in the fetuses of ZIKV-infected mothers, which was greatly enhanced by DENV immunity or 4G2-injection of mother mice. ZIKV infection was also enhanced by DENV-specific antibodies both in fetuses and in the mothers' spleens. Use of FcRN-deficient mice showed that there was significantly increased trans-placental infection in an FcRN-dependent manner, leading to a greater incidence of microcephaly in the fetuses of DENV-immune mothers.
Conclusion: We show that DENV-specific antibodies in expectant mothers results in a severe microcephaly like-syndrome during ZIKV infection. Furthermore, fetal infection was promoted by FcRN. Our results raise caution since ZIKV epidemic regions are also endemic to DENV. Background: Since 2015, Brazil has experienced an unprecedented Zika virus outbreak. A devastating consequence of this viral infection is congenital Zika infection (CZI), which is transmitted from pregnant women to newborns. Most descriptions and publications regarding CZI focus on the clinical presentation of newborns and infants with microcephaly. Scarce information is available concerning children without microcephaly born from infected mothers.
During 2016, in the city of Salvador (Bahia, Brazil), a crosssectional study enrolled 103 pregnant women who reported an exanthematous disease during pregnancy. Of these, 69 (67%) presented anti-Zika antibodies at the time of delivery. A total of 7 (6.8%) newborns were diagnosed with microcephaly, while 96 (93.2%) were classified as newborns without microcephaly.
Methods & Materials:
In June 2017, we began a prospective follow-up of these infants without microcephaly exposed to Zika Virus in utero by evaluating neurodevelopment delays, performing neurological examinations and applying the Bayley Scales of Infant Development III (BSID-III), Mental Development Index (MDI) and Bayley-III cognitive and language scales. Auditory evaluations were performed by Otoacustic emissions (OAE) and Brainstem Auditory Evoked Potential (BAEP).
Results: To date we have evaluated 18 infants, mean age 1.7 years. Of these, 55.6% are male and 61% were delivered by C-section. Anti-Zika IgG serology was positive in 75% and three (16.6%) presented positivity for Zika by PCR on urine samples within 24 h of birth. Based on head circumference (HC) at time of birth, all were classified as normal by the Intergrowth scale and currently fall within normal HC percentiles. Cognitive delay was identified in five (33%) infants, language delay in four (26.6%) and motor delay in two (13.3%).
Conclusion: Our preliminary results indicate that in utero exposure to Zika virus could be associated with neurodevelopmental delay, even in children born without microcephaly at birth. Currently, only microcephalic infants are referred to specialized care, while normocephalic children are maintained in primary health care. We believe that all newborns exposed to Zika in utero should be referred to specialized centers for the early detection of neurodevelopmental delays and timely intervention. 
